An observational study in Hematopoietic Malignancies, Haploidentical Hematopoietic Stem Cell Transplantation and Donor, sponsored by The First Affiliated Hospital of Soochow University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by The First Affiliated Hospital of Soochow University · Observational
This observational study aims to emulate a hypothetical pragmatic, multicenter, non-blinded clinical trial enrolling adult patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with grafts derived from either cousin or sibiling donors.
The main research question is whether cousin donor-derived haplo-HSCT is associated with inferior clinical outcomes relative to sibling donor-derived haplo-HSCT.
Study participants consist of adult patients diagnosed with hematological malignancies who underwent cousin or sibiling haplo-HSCT between 2017 and 2024, and all eligible recipients will receive regular follow-up assessments.
1,464 studies on the registry are indexed under Hematologic Neoplasms; 432 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 182 across 325 observational studies indexed under Hematologic Neoplasms.
Browse Hematologic Neoplasms studies →The First Affiliated Hospital of Soochow University is the lead sponsor of 252 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This multicenter, retrospective observational study included adult patients with hematological malignancies undergoing their first haploidentical hematopoietic stem cell transplantation at four clinical centers between 2017 to 2024. Eligible patients were identified through retrospective clinical records and stratified by donor kinship recorded at transplant, classified as either cousin or sibling donor graft recipients.
Exclusion Criteria:
Patients who underwent haploidentical hematopoietic stem cell transplantation with cousin donors. Grouping was based on donor age recorded in retrospective clinical data.
Patients who underwent haploidentical hematopoietic stem cell transplantation with sibling donors. Grouping was based on donor age recorded in retrospective clinical data.
Overall survival
estimated overall survival at 2 year
Time frame: 2 years after transplantation
Graft-versus-host disease-free and relapse-free survival
estimated graft-versus-host disease-free and relapse-free survival at 2 year
Time frame: 2 years after transplantation
Cumulative incidence of acute graft-versus-host disease
estimated cumulative incidence of acute graft-versus-host disease at 180 day
Time frame: 180 days after transplantation
Cumulative incidence of chronic graft-versus-host disease
estimated cumulative incidence of chronic graft-versus-host disease at 2 year
Time frame: 2 years after transplantation
Cumulative incidence of relapse
estimated cumulative incidence of relapse at 2 year
Time frame: 2 years after transplantation
Non-relapse mortality
estimated non-relapse mortality at 2 year
Time frame: 2 years after transplantation
Cumulative incidence of grade III-IV acute graft-versus-host disease
estimated cumulative incidence of grade III-IV acute graft-versus-host disease at 180 day
Time frame: 180 days after transplantation
Cumulative incidence of extensive chronic graft-versus-host disease
estimated cumulative incidence of extensive chronic graft-versus-host disease at 2 year
Time frame: 2 years after transplantation
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Soochow University